In this episode, we’re joined by Martin Borch Jensen, Co-Founder and Chief Scientific Officer at Gordian Biotechnology and President of Norn Group, a non-profit dedicated to accelerating research and development of therapies targeting the biology of ageing.

Patrick and Martin discuss the phenomenon known as the “ageing problem,” how understanding biological age could crack the code on age-related diseases, and the challenges of building a company in a field with no business model blueprint.